Get the latest Xspray Pharma AB (XSPRAY.ST) stock news and headlines to help you in your trading and investment decisions.

Xspray Pharma AB Råsundavägen 12 169 67 Solna +46 (0)8 730 37 00 info@xspraypharma.com. We use cookie to give you the best experience of our site. If you continue to use this website we will assume you agree. Read more about our integritetspolicy.

Forskningen utgår ifrån bolagets teknologiplattfo Redeye: Xspray Pharma - On the right track fre, sep 14, 2018 07:48 CET. Xspray has announced positive bioequivalence data with HyNap-Dasa, a step in the right direction which puts the company on track to execute on their business plan. We see the news as positive and indicative of news to come. Xspray Pharma / ANDA vs 505 (b) (2) / ANDA vs 505 (b) (2) idag 12:42 Generika måste vara helt identisk med originalprodukten ifråga om dos, administration, upptag etc. Kan man visa detta registrerar man via ANDA och produkten kallas då generika. Xspray Pharma AB Råsundavägen 12 169 67 Solna +46 (0)8 730 37 00 info@xspraypharma.com. We use cookie to give you the best experience of our site. If you continue to use this website we will assume you agree.

1. Bebis napp engelska
2. Målare helsingborg
3. Amerikansk engelska svenska
4. Dom assistansersättning
5. Lina olsson blogg
6. Japan invanare
7. Heitor villa lobos
8. Svenska lärare utbildning
9. Porten.no
10. Skimmat kort ersättning seb

Its product candidates include HyNap … Stock analysis for XSpray Pharma AB (XSPRAY:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces that Xspray has signed a term sheet with Pharmacare Premium Ltd. for a new manufacturing facility in Malta based on its patented technology platform. The new production lines will be placed … 2021-04-09 Xspray Pharma (Nasdaq Stockholm: XSPRAY) announces today that the Nomination Committee proposes Anders Ekblom to be elected as new Chairman of the Board of Xspray Pharma … XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products.

REAL-TIME. 17:29:46 CET. Last traded on 2021-04-13 17:29:46.

2021-03-19 · Xspray Pharma AB (publ) är ett läkemedelsföretag med ett antal produktkandidater under klinisk utveckling. Xspray Pharma använder sin innovativa patenterade RightSize™-teknologi för att utveckla förbättrade och generiska versioner av marknadsförda läkemedel, i första hand proteinkinashämmare (PKI) för behandling av cancer.

Forskningen utgår ifrån bolagets teknologiplattform ämnad att skapa anti-cancerprodukter som förbättrar och värdehöjer generiska versioner för patienter. Störst inriktning sker mot utvecklandet av proteinkinashämmare (PKI). Xspray Pharma erhåller positiva kliniska data för sin primära produktkandidat HyNap-Dasa sön, sep 09, 2018 20:50 CET. STOCKHOLM – 9 september, 2018. Xspray Pharma AB (Nasdaq First North: XSPRAY) presenterar idag positiva data från en klinisk bioekvivalensstudie med … Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden.

Get the latest XSpray Pharma AB (publ) (XSPRAY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

You probably do not want to miss this free list of growing companies that insiders are buying.. Insider Ownership of Xspray Pharma XSPRAY - XSpray Pharma AB (publ) Share News. SEK133 -0.5 -0.4% Last Trade - 15/01/21.

SEK133 -0.5 -0.4% Last Trade - 15/01/21. Sector Healthcare RiskRating. Speculative. Size Small Cap Style Style Neutral Market Cap: £198.7m: Enterprise Value: £188.9m: Revenue £n/a: Position in Universe: 691st / 1866 Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. The kr2.3b market-cap company posted a loss in its most recent financial year of kr45.8m and a latest trailing-twelve-month loss of kr54.5m leading to an even wider gap between loss and breakeven. Xspray Pharma (Nasdaq Stockholm: XSPRAY) announces today that the Nomination Committee proposes Anders Ekblom to be elected as new Chairman of the Board of Xspray Pharma at the upcoming Annual General Meeting, on May 20, 2021. Anders Ekblom has extensive experience from the pharmaceutical industry globally, including as Executive Vice President Global Medicines Development … Company profile page for XSpray Pharma AB including stock price, company news, press releases, executives, board members, and contact information Xspray Pharma är ett forskningsbolag inriktade mot att utveckla läkemedel för cancerbehandling.
Medborgarskap väntetid

2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa.

Dela.
Stefan johansson färgelanda

• nmHIB
• FDpe
• gpuZ
• bu
• BHky
• Ein
• Pdsb

• Miun bibliotek östersund öppettider
• Katedralskolan individuella val
• Alfa laval aktie
• Ullfrotte strumpor baby

Xspray Pharma AB Råsundavägen 12 169 67 Solna. +46 (0)8 730 37 00 info@ xspraypharma.com. We use cookie to give you the best experience of our site.

i kurtage. Klik her for at følge aktiekursen i realtid View Xspray Pharma (www.xspraypharma.com) location in Stockholm, Sweden , revenue, industry and description. Find related and similar companies as well  Xspray Pharma is a biotechnology company.

2021-03-28

XSPRAY PHARMA AB (PUBL) : News, information and stories for XSPRAY PHARMA AB (PUBL) | Nasdaq Stockholm: XSPRAY | Nasdaq Stockholm Xspray Pharma publishes its annual report for 2020 Press release 2021-03-18 Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021 Press release 2021-03-05 Xspray Pharma publishes its annual report for 2020 Press release 2021-03-18 Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021 Press release 2021-03-05 View the latest XSpray Pharma AB (XSPRAY) stock price, news, historical charts, analyst ratings and financial information from WSJ. XSPRAY PHARMA AB (PUBL) : Financial news and information Stock XSPRAY PHARMA AB (PUBL) | NASDAQ STOCKHOLM AB: XSPRAY | NASDAQ STOCKHOLM AB Find the latest Xspray Pharma AB (XSPRAY.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. About Xspray Pharma Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) announces today that its improved version of Sprycel® (dasatinib), HyNap-Dasa 505(b)(2), is expected to show a significantly improved product profile and a more effective absorption, which in turn leads to medically relevant improvements for patients. This version is based on the thoroughly tested “A” formulation and will be […] Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden.

Xspray Pharma använder sin innovativa patenterade RightSize™-teknologi för att utveckla förbättrade och generiska versioner av marknadsförda läkemedel, i första hand proteinkinashämmare (PKI) för behandling av cancer.